C4orf3 Inhibitors
C4orf3 inhibitors are characterized by their ability to impede the protein's function through strategic interference with multiple cellular signaling cascades. Compounds like Rapamycin and its analogs, Torin 1, PP242, and AZD2014, directly thwart mTOR pathway signaling, a critical route for the regulation of cell growth and proliferation that C4orf3 is a part of. By inhibiting mTORC1 and mTORC2, these inhibitors stymie the downstream effects that would otherwise culminate in the activation of C4orf3, leading to a diminution of its involvement in cellular processes. Similarly, PI3K inhibitors, including LY 294002, Wortmannin, and ZSTK474, curtail the PI3K/AKT/mTOR axis, a pathway integral to C4orf3's role in cell survival and proliferation, thus indirectly diminishing the protein's functional activity. The specific blockage of PI3K halts the propagation of signals to AKT and mTOR, stifling the activation of C4orf3.
In parallel, inhibitors targeting the MAPK pathway, such as PD 98059, U0126, and SB 203580, disrupt the MAPK/ERK and p38 MAPK pathways, both of which are pivotal for the transmission of extracellular signals that influence the function of C4orf3. By inhibiting MEK1/2, U0126 obviates the activation of ERK1/2, attenuating the signaling processes that would enhance C4orf3 activity, especially in the context of cell differentiation and proliferation. The JNK pathway, implicated in stress response and modulated by SP600125, and the p70 S6 kinase pathway, targeted by PF 4708671, further exemplify the strategic blockade at junctures critical to C4orf3's operation. The inhibition of these kinases results in a weakened stress response and reduced protein synthesis, respectively, thereby contributing to the comprehensive diminution of C4orf3's functional spectrum within the cell. Collectively, these inhibitors act in concert to suppress C4orf3's activity by dismantling the signaling infrastructure that supports its functional engagement.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin forms a complex with FKBP12 that binds to and inhibits the mTOR complex 1 (mTORC1). C4orf3 is involved in the regulation of cell growth and proliferation through pathways downstream of mTORC1. Inhibition of mTORC1 by rapamycin would therefore lead to diminished C4orf3 activity due to reduced cellular growth signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. The PI3K/AKT/mTOR signaling pathway is connected to numerous cellular processes including those regulated by C4orf3. Inhibition of PI3K will lead to decreased AKT phosphorylation and subsequent mTOR activity, which would diminish C4orf3 function in growth and proliferation signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor which interrupts the MAPK/ERK pathway. Since C4orf3 is involved in cellular processes that are downstream of MAPK signaling, blocking MEK would lead to reduced ERK activation and therefore decrease C4orf3's functional involvement in these signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in stress responses, and C4orf3 function is implicated in pathways responsive to cellular stress. Inhibition of p38 MAPK would therefore likely reduce stress signal transduction involving C4orf3. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another inhibitor of PI3K. By inhibiting PI3K, it prevents the activation of AKT and downstream signaling molecules such as mTOR, leading to a decrease in C4orf3 activity related to cell survival and proliferation. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR that affects both mTORC1 and mTORC2 complexes. Given that C4orf3 is associated with mTOR signaling, PP242 would reduce its activity by broadly inhibiting mTOR-dependent growth and survival pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the stress-activated protein kinase pathways, and inhibition of JNK would therefore limit stress signaling, consequently diminishing the function of C4orf3 in stress response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a highly selective inhibitor of both MEK1 and MEK2. By inhibiting these kinases, U0126 prevents the activation of ERK1/2, leading to reduced signaling through pathways where C4orf3 operates, particularly those involved in cell proliferation and differentiation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor which impacts both mTORC1 and mTORC2. By inhibiting mTOR signaling, Torin 1 would attenuate the function of C4orf3 in processes such as cell growth and metabolic regulation. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF 4708671 is a selective inhibitor of p70 S6 kinase, a downstream target of mTORC1. Inhibition of p70 S6 kinase will decrease protein synthesis and cell growth, processes in which C4orf3 is indirectly involved, leading to its functional inhibition. | ||||||